- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sanofi India Gets Relief as GST Authority Drops Rs 23.73 Crore Excess ITC Notice

Mumbai: Sanofi India Limited has received an adjudication order from the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, dropping a Goods and Services Tax (GST) show cause notice that had alleged excess availment of Input Tax Credit (ITC) amounting to Rs 23.73 crore for the financial year 2022-23.
In a regulatory filing, the pharmaceutical company informed the stock exchanges that the proceedings were concluded following the payment of Rs 17,680, comprising Rs 10,128 towards Central Goods and Services Tax (CGST) and State Goods and Services Tax (SGST), and Rs 7,552 as interest. The payment related to certain blocked credit items.
The matter originated from a show cause notice dated September 25, 2026, issued by the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru. The notice alleged that Sanofi India had availed excess Input Tax Credit during the period from April 2022 to March 2023 and proposed to determine a tax liability of Rs 23,73,76,507.
Following the notice, the company submitted its explanations and representations before the tax authorities. After considering the submissions, the Commercial Tax Officer issued an adjudication order dated November 16, 2026, under Section 73 of the Karnataka Goods and Services Tax Act, 2017.
As per the adjudication order, the proceedings were concluded upon payment of the applicable tax and interest amounting to Rs 17,680. The authority confirmed that no further amount was payable by the company and dropped the show cause notice.
Sanofi India further clarified that the order would have no material impact on its financial, operational or other activities.
Sanofi India Limited is part of the global Sanofi Group, a biopharmaceutical company focused on developing and delivering medicines and healthcare solutions across various therapeutic areas. Its operations in India include pharmaceutical products catering to multiple healthcare needs.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

